From the very start of the integration of IDS and Euroimmun activities, harmonizing and expanding the training programs for the IDS random access instruments was recognized as a strategic priority. This endeavor required extensive, open communication and close collaboration between the two organizations. Throughout the integration process, we successfully navigated several key challenges: Decentralized trainings: […]
In June 2026, Euroimmun received official confirmation from TÜV Rheinland LGA Products GmbH that all of its in vitro diagnostic devices currently on the market under Directive 98/79/EG (IVDD) may continue to be marketed in the European Union. This confirmation applies to all devices for which Euroimmun had submitted a corresponding application based on EU
Circulating uromodulin may help identify kidney dysfunction in sickle cell disease while conventional kidney markers remain within reference range, as demonstrated in a recent collaborative study conducted with Euroimmun, University Hospital Essen, Germany and other academic and clinical partners. A diagnostic challenge Sickle cell nephropathy is a major cause of illness and early death
Both experienced the journey of integrating IDS structures into Euroimmun firsthand: Anke Behne-Wachholz, Head of Customer Technical Operations, and Emma Storey, lead for the ChLIA Technical Services team, which consists of colleagues from both Euroimmun and IDS and is dedicated to supporting customers with questions and issues related to ChLIA automation. “Looking back on the
A current multicentre study shows that anti-nephrin autoantibodies can be a reliable biomarker for idiopathic nephrotic syndrome, which occurs in diseases such as minimal change disease (MCD). These antibodies were much more frequent in patients with the respective diseases than in those with other kidney diseases or in healthy persons. The antibody level also correlates
